Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1409-1416

  Markou, Athina ^a   Pappa, Theodora ^a   Kaltsas, Gregory ^b   Gouli, Aggeliki ^a   Mitsakis, Kostas ^a   Tsounas, Panayiotis ^a   Prevoli, Anastasia ^a   Tsiavos, Vaios ^a   Papanastasiou, Labrini ^a   Zografos, George ^a   Chrousos, George P ^c   Piaditis, George P ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CORTICOTROPIN; DEXAMETHASONE; FLUDROCORTISONE ACETATE; HYDROCORTISONE; POTASSIUM; PRASTERONE SULFATE; SODIUM; SODIUM CHLORIDE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; BLOOD PRESSURE; CASE CONTROL STUDY; CHEMICAL ANALYSIS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HORMONE DETERMINATION; HORMONE INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SODIUM BLOOD LEVEL; TERTIARY HEALTH CARE;

ADULT; AGED; ALDOSTERONE; BLOOD PRESSURE; CASE-CONTROL STUDIES; COHORT STUDIES; DEXAMETHASONE; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DISEASE PROGRESSION; FEMALE; FLUDROCORTISONE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; ODDS RATIO; SEX RATIO;

EID: 84876255455     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3353     Document Type: Article

References (32)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep. 2011;13:163-172.
3. Rossi GP, Sacchetto A, Pavan E, Scognamiglio R, Pietra M, Pessina AC. Left ventricular systolic function in primary aldosteronism and hypertension. J Hypertens. 1998;16:2075-2077.
4. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27.
5. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48: 232-238.
6. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88-90.
7. Fritsch Neves M, Schiffrin EL. Aldosterone: arisk factor for vascular disease. Curr Hypertens Rep. 2003;5:59-65.
8. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17:199-204.
9. Carey RM. Aldosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2010;17:194-198.
10. Huang BS, Leenen FH. Mineralocorticoid actions in the brain and hypertension. Curr Hypertens Rep. 2011;13:214-220.
11. Nishimura M, Uzu T, Fujii T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999;33: 261-266.
12. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93:3266-3281.
13. Young WF. Primary aldosteronism: renaissance ofa syndrome. Clin Endocrinol (Oxf). 2007;66:607-618.
14. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2006;9:2618-2623.
15. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003;21:2149-2157.
16. Gouli A, Kaltsas G, Tzonou A, et al. Highprevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest. 2011;41:1227-1236.
17. Crabbe J, Reddy WJ, Ross EJ, Thorn GW. The stimulation of aldosterone secretion by adrenocorticotropic hormone (ACTH). J Clin Endocrinol Metab. 1959;19:1185-1191.
18. Tucci JR, Espiner EA, Jagger PI, Pauk GL, Lauler DP. ACTH stimulation of aldosterone secretion in normal subjects and in patients with chronic adrenocortical insufficiency. J Clin Endocrinol Metab. 1967;27:568-575.
19. Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350:151-162.
20. Pappa T, Papanastasiou L, Kaltsas G, et al. Pattern of adrenal hormonal secretion in patients with adrenal adenomas: the relevance of aldosterone in arterial hypertension. J Clin Endocrinol Metab. 2012;97:E537-E545.
21. Piaditis GP, Kaltsas GA, Androulakis II, et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf). 2009;71:772-778.
22. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
23. Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res. 2011;34:98-102.
24. Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathy-roidism. Arq Bras Endocrinol Metab. 2010;54:106-109.
25. Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent conditionora silent threat?Arq Bras Endocrinol Metab. 2011;55:314-317.
26. Carneiro-Pla D, Solorzano C. A summary of the new phenomenon of normocalcemic hyperparathyroidism and appropriate management. Curr Opin Oncol. 2012;24:42-45.
27. Brooks RV, Felix-Davies D, Lee MR, Robertson PW. Hyperaldosteronism from adrenal carcinoma. Br Med J. 1972;1:220-221.
28. Medeau V, Moreau F, Trinquart L, et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol (Oxf). 2008;69:20-28.
29. Mulatero P, Veglio F, Pilon C, et al. Diagnosis of glucocorticoid- remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab. 1998;83:2573-2575.
30. McManus RJ, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. BMJ. 2012;344:e181.
31. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261-273.
32. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol. 2000;85:1199-1206.